Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?

References

• van Panhuis WG, Grefenstette J, Jung SY, Chok NS, Cross A, Eng H, Lee BY, Zadorozhny V, Brown S, Cummings D, Burke DS. Contagious diseases in the United States from 1888 to the present. New Engl J Med 2013; 369:2152-8; PMID:24283231; http://dx.doi.org/10.1056/NEJMms1215400
   PubMed Web of Science ®Google Scholar
• Organization WH. Global vaccine action plan 2011-2020. 2013. http://www.who.int/immunization/global_vaccine_action_plan/gvap_secretariat_report_2015.pdf?ua=1
   Google Scholar
• De Gregorio E, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 2014; 14:505-14; PMID:24925139; http://dx.doi.org/10.1038/nri3694
   PubMed Web of Science ®Google Scholar
• Pasteur L. De l'attenuation du virus du cholera des poules. C R Acad Sci 1880; 673-80
   Google Scholar
• Organization WH. Tuberculosis Factsheet N°104. 2014. http://www.who.int/mediacentre/factsheets/fs104/en
   Google Scholar
• Calmette AG, C. Contribution à l'étude de l'immunité antituberculose chez les bovidés. Ann Inst Pasteur 1914; 28:329-37
   Google Scholar
• Romanus V, Hallander HO, Wahlen P, Olinder-Nielsen AM, Magnusson PH, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tubercle lung Dis: Off J Int Union Against Tuberculosis Lung Dis 1995; 76:300-10; PMID:7579311; http://dx.doi.org/10.1016/S0962-8479(05)80028-0
   PubMed Web of Science ®Google Scholar
• Buddle BM, Parlane NA, Wedlock DN, Heiser A. Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans. Transbound Emerg Dis 2013; 60 Suppl 1:136-46; PMID:24171859; http://dx.doi.org/10.1111/tbed.12092
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013; 8:360-76; PMID:23316023; http://dx.doi.org/10.1002/cmdc.201200487
   PubMed Web of Science ®Google Scholar
• Andersen P. TB vaccines: progress and problems. Trends Immunol 2001; 22:160-8
   PubMed Web of Science ®Google Scholar
• Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010; 22:411-6; PMID:11286732; PMID:20466528; http://dx.doi.org/10.1016/j.coi.2010.04.004
   PubMed Web of Science ®Google Scholar
• Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276:1420-2; PMID:9162010; http://dx.doi.org/10.1126/science.276.5317.1420
   PubMed Web of Science ®Google Scholar
• D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, Castiglione N, Vanonckelen A, Palfliet K, Huygen K. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 2003; 71:483-93; PMID:12496199; http://dx.doi.org/10.1128/IAI.71.1.483-493.2003
   PubMed Web of Science ®Google Scholar
• Junqueira-Kipnis AP, Marques Neto LM, Kipnis A. Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines. Front Immunol 2014; 5:188; PMID:AMBIGUOUS; http://dx.doi.org/10.3389/fimmu.2014.00188
   PubMedGoogle Scholar
• van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010; 28:3571-81; PMID:20226890; http://dx.doi.org/10.1016/j.vaccine.2010.02.094
   PubMed Web of Science ®Google Scholar
• Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, Bennett S, Andersen P, Kromann I, Hoff ST, et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine 2015; 33:3592-9; PMID:26048780; http://dx.doi.org/10.1016/j.vaccine.2015.05.036
   PubMed Web of Science ®Google Scholar
• Singh S, Saraav I, Sharma S. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis. Vaccine 2014; 32:712-6; PMID:24300592; http://dx.doi.org/10.1016/j.vaccine.2013.11.065
   PubMed Web of Science ®Google Scholar
• Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 2015; 33:4130-40; PMID:26095509; http://dx.doi.org/10.1016/j.vaccine.2015.06.051
   PubMed Web of Science ®Google Scholar
• Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P, Koutsoukos M, Moris P, Cain D, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 2009; 5:475-82; PMID:19587528; http://dx.doi.org/10.4161/hv.8570
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, Moris P, De Kock E, Clement F, Dubois MC, Koutsoukos M, Demoitie MA, Cohen J, et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010; 17:1763-71; PMID:20861328; http://dx.doi.org/10.1128/CVI.00133-10
   PubMed Web of Science ®Google Scholar
• Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapeliere P, Moris P, Demoitie MA, Mettens P, Vinals C, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb) 2013; 93:179-88; PMID:23219236; http://dx.doi.org/10.1016/j.tube.2012.10.011
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitie MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013; 31:2196-206; PMID:22643213; http://dx.doi.org/10.1016/j.vaccine.2012.05.035
   PubMed Web of Science ®Google Scholar
• Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, Moris P, Hatherill M, Ofori-Anyinam O, Hanekom W, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 2015; 33:4025-34; PMID:26072017; http://dx.doi.org/10.1016/j.vaccine.2015.05.088
   PubMed Web of Science ®Google Scholar
• Devasundaram S, Deenadayalan A, Raja A. In silico analysis of potential human T Cell antigens from Mycobacterium tuberculosis for the development of subunit vaccines against tuberculosis. Immunol Invest 2014; 43:137-59; PMID:24467664; http://dx.doi.org/10.3109/08820139.2013.857353
   PubMed Web of Science ®Google Scholar